[ad_1]
On this occasion, the possible Corona vaccine from Globe Biotech of Bangladesh has also drawn attention outside the country. The World Health Organization’s list of groundbreaking candidates includes three vaccines, including this potential Globe Biotech vaccine. Nepal has been ahead of Banquid from the start. The government of Nepal has shown interest in testing the vaccine in that country. At the same time, the country has said it has received 2 million doses of Globe Biotech vaccine.
Meanwhile, Globe Biotech has signed a preliminary agreement with the Government of Nepal. Nepalese Ambassador to the Globe Office in Dhaka on Thursday. The agreement was signed between Banshidhar Mishra and Harunur Rashid, Chairman of Globe.
On the occasion, the Ambassador of Nepal said: ‘Bangladesh and Nepal have much in common in terms of nature, environment and human physical condition. As a result, we have become interested in this brand in the world. If this vaccine is successful, it will be much bigger for us. It will be a great achievement for Bangladesh.
Globe president said: “An organization called Anmal in Nepal has shown interest in obtaining 20 lakh doses of vaccine from us. Also, the Government of Nepal will test our ticker there. This is another milestone for us. ‘ At the same time, several other countries have already started contacting them to pre-book vaccination, he said.
According to Globe Biotech sources, they have been working on the coronavirus vaccine since March 6. They have periodically been successful in experimental applications in animal bodies. Based on this, the International Center for Diarrhea Research Bangladesh (ICDDRB) has signed an agreement with Globe to test this vaccine on the human body. ICDDRBE will now appeal to the government to arrange other necessary matters.
Meanwhile, Bangabandhu Sheikh Mujib Medical University (BSMMU) will conduct a trial of a vaccine invented by the France-based Sanofi Pastor Company. BSMMU sources said that the agreement process between the two organizations is ongoing. Furthermore, the process of testing a ticker from an Indian biotech company in Bangladesh has been pending for a long time.
[ad_2]
